An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer

CONCLUSIONS: In this Phase I study, DMUC4064A demonstrated a tolerable safety profile along with encouraging efficacy in the indication of platinum-resistant OC.PMID:34627611 | DOI:10.1016/j.ygyno.2021.09.023
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Source Type: research